Methods and compositions for inhibiting CD32b expressing cells

Patent metadata

Field	Value
Publication number	US-9902773-B2
Application number	US-201414328562-A
Country	US
Kind code	B2
Filing date	Jul 10, 2014
Priority date	May 30, 2007
Publication date	Feb 27, 2018
Grant date	Feb 27, 2018

Abstract

The present invention relates to immunoglobulins that bind FcγRIIb+ cells and coengage the antigen on the cell's surface and an FcγRIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.

First claim

We claim:

1. A protein comprising an Fc variant comprising at least amino acid modifications S267E and L328F as compared to a parent Fc polypeptide, wherein numbering is according to the EU index according to Kabat.

2. A pharmaceutical composition comprising protein according to claim 1 , and a pharmaceutically acceptable carrier.

3. A protein comprising an Fc variant comprising at least amino acid modifications S267E and L328F as compared to a parent Fc polypeptide, wherein numbering is according to the EU index according to Kabat, wherein said Fc variant has increased binding affinity to FcγRIIb as compared to the parent Fc polypeptide.

Assignees

• Xencor Inc

Inventors

• Chu Seung Yup
• Desjarlais John R
• Karki Sher Bahadur
• Lazar Gregory Alan
• Moore Gregory L
• Vostiar Igor

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title